IndiaOne Finance - Company Dashboard

Governance Classic Home

Krebs Biochemicals & Industries LtdPharmaceuticalsINE268B01013

Valuation

Market Cap₹123.56 Cr

TTM PE-8.76x

Forward PE-11.65x

PEG0.52

Book Value—

P/B—

TTM EPS₹-6.54

Fwd EPS₹-4.92

TTM Revenue₹25.23 Cr

TTM PAT₹-14.09 Cr

TTM EBITDA₹-2.54 Cr

TTM EBIT₹-8.96 Cr

Last Qtr PAT₹-2.34 Cr

Last Qtr EBITDA₹0.83 Cr

Last Qtr EBIT₹-0.76 Cr

Profitability

ROE—

ROCE-11.00%

TTM NPM-55.85%

TTM EBITDA %-10.07%

Curr OPM-34.73%

Last OPM-26.56%

Curr NPM—

Last NPM—

Curr EPS₹-1.15

Last EPS₹-1.09

Balance sheet

Equity₹21.56 Cr

Reserve₹-184.32 Cr

Total Debt₹224.84 Cr

D/E—

Interest %-75.81%

Curr Interest₹1.88 Cr

Price / range

Close₹57.31

vs 52W High-29.94%

vs 52W Low+48.78%

MA50—

MA200—

Returns

1D+3.30%

1W-2.74%

1M+2.42%

3M-11.74%

6M+16.37%

1Y-26.87%

2Y-38.60%

3Y-12.06%

5Y-70.84%

Diwali-16.75%

Sector peers — Pharmaceuticals

Company	Close	Mkt Cap	TTM P/E	ROE
SUNPHARMA	1837.30	₹4.41L Cr	148.17	3.58%
DIVISLAB	9375.00	₹2.49L Cr	84.62	17.55%
TORNTPHARM	4840.00	₹1.84L Cr	78.80	25.43%
ZYDUSLIFE	1160.00	₹1.16L Cr	33.21	12.96%
CIPLA	1394.50	₹1.13L Cr	36.64	8.93%
LAURUSLABS	1954.00	₹1.06L Cr	120.92	16.46%
AUROPHARMA	1734.00	₹99.77K Cr	38.79	6.84%
DRREDDY	1185.00	₹98.91K Cr	148.68	1.75%

Financial Results

Quarterly and yearly P&L · YoY % on Revenue, Total Income, Expenditure, EBITDA, EBIT, PBT, Net Profit and EPS

Metric	Jun-26	Mar-26	Dec-25	Sep-25	Jun-25	FY25-26
Revenue	6.98+27.4%	6.81	7.27	4.17	5.48	23.73
Other Income	0.16	2	0	0.01	0.01	2.03
Total Income	7.14+30.1%	8.81	7.28	4.17	5.49	25.76
Interest	1.88	1.91	1.79	1.73	1.65	7.09
Expenditure	-9.62+11.1%	-11.15	-10.41	-10.32	-10.82	-42.69
PBDT	0	0	0	0	0	0
EBITDA	0.83+139.7%	-0.86	0.29	-2.80	-2.09	-5.45
Depreciation	-1.59	-1.57	-1.64	-1.62	-1.60	-6.42
EBIT	-0.76+79.4%	-2.43	-1.35	-4.42	-3.69	-11.87
PBT	-2.48+53.4%	-2.34	-3.13	-6.14	-5.32	-16.93
Tax	0	0	0	0	0	0
Equity	21.56	21.56	0	0	21.56	21.56
OPM	-34.73	-26.56	-42.99	-147.42	-96.90	-65.74
Net Profit	-2.48+53.4%	-2.34	-3.13	-6.14	-5.32	-16.93
NPM	-34.73	-26.56	-42.99	-147.42	-96.90	-65.74
EPS	-1.15+53.4%	-1.09	-1.45	-2.85	-2.47	0

Yearly results

Last 6 financial years · YoY % vs previous FY

Metric	FY 25-26	FY 24-25	FY 23-24	FY 22-23	FY 21-22	FY 20-21
Revenue	23.73-45.2%	43.31-14.1%	50.42-3.3%	52.13-1.5%	52.94-1.4%	53.70
Other Income	2.03	0.71	0.45	0.62	7.92	0.62
Total Income	25.76-41.5%	44.02-13.5%	50.87-3.6%	52.76-13.3%	60.86+12.0%	54.32
Expenditure	-42.69+39.8%	-70.94-0.5%	-70.60+8.8%	-77.45+26.5%	-105.39-27.5%	-82.68
Interest	-7.09	-5.91	-4.69	-2.97	-5.39	-6.28
PBDT	0	0	0	0	0	0
EBITDA	-5.45+63.7%	-15.03-72.4%	-8.72+44.8%	-15.79+61.3%	-40.76-131.9%	-17.58
Depreciation	-6.42	-6.69	-6.77	-6.56	-6.30	-5.12
EBIT	-11.87+45.3%	-21.72-40.2%	-15.49+30.7%	-22.35+52.5%	-47.06-107.3%	-22.70
PBT	-16.93+37.1%	-26.92-36.4%	-19.73+20.1%	-24.69+44.6%	-44.53-57.0%	-28.36
Tax	0	-0.02	0	0	0	0
Equity	21.56	21.56	0	0	0	0
OPM (%)	-65.74	-61.16	-39.00	-47.00	-73.00	-52.00
Net Profit	-16.93+37.2%	-26.94-36.5%	-19.73+20.1%	-24.69+44.6%	-44.53-57.0%	-28.36
NPM (%)	-65.74	-61.20	-39.00	-47.00	-73.00	-52.00
EPS (Rs)	0	0+100.0%	-9.16+18.9%	-11.30+45.7%	-20.81-43.2%	-14.53
CEPS	0	0	-9.16	-11.30	-20.81	-14.53

Metric	FY25-26
Revenue	23.73
Other Income	2.03
Total Income	25.76
Interest	7.09
Expenditure	-42.69
PBDT	0
EBITDA	-5.45
Depreciation	-6.42
EBIT	-11.87
PBT	-16.93
Tax	0
Equity	21.56
OPM	-65.74
Net Profit	-16.93
NPM	-65.74
EPS	0

Yearly results

Last 6 financial years · YoY % vs previous FY

Metric	FY 25-26	FY 24-25
Revenue	23.73-45.2%	43.31
Other Income	2.03	0.71
Total Income	25.76-41.5%	44.02
Expenditure	-42.69+39.8%	-70.94
Interest	-7.09	-5.91
PBDT	0	0
EBITDA	-5.45+63.7%	-15.03
Depreciation	-6.42	-6.69
EBIT	-11.87+45.3%	-21.72
PBT	-16.93+37.1%	-26.92
Tax	0	-0.02
Equity	21.56	21.56
OPM (%)	-65.74	-61.16
Net Profit	-16.93+37.2%	-26.94
NPM (%)	-65.74	-61.20
EPS (Rs)	0	0
CEPS	0	0

Corporate Actions

Dividends, bonus issues, and stock splits

Dividend

No dividend history.

Bonus

No bonus history.

Split

No split history.

Financial Results

Standalone

Yearly results

Yearly

Consolidated

Yearly results

Yearly

Corporate Actions

Dividend

Bonus

Split